Lymphangioleiomyomatosis (LAM) is a multisystem disease of women, affecting lungs, kidneys, and lymphatics. It is caused by the proliferation of abnormal smooth muscle-like LAM cells, with mutations and loss of heterozygosity in the TSC1 or, more frequently, TSC2 genes. Isolated pulmonary LAM cells have been difficult to maintain in culture, and most studies of LAM lung cells involve mixtures of TSC2 wild-type and TSC2-null cells. A clonal population of LAM lung cells has not been established, making analysis of the cells challenging. Cell lines have been established from angiomyolipomas, a common manifestation of LAM, and from tumors from patients with TSC. Circulating LAM cells have also been isolated from blood and other body fluids. LAM cells may also be identified in clusters apparently derived from lymphatic vessels. Genetics, patterns of antigen expression, and signaling pathways have been studied in LAM lung tissue and in LAM cell models, although rarely all in the same study. We show here that LAM cells manifest differences in these characteristics, depending on the source investigated, suggesting further studies.
Lymphangioleiomyomatosis (LAM) is a multisystem disease occurring predominantly in women, involving lungs, the lymphatic system, and kidneys ( Figure 1 ). LAM can occur sporadically or in conjunction with tuberous sclerosis complex (TSC), an autosomal dominant disorder characterized by hamartomatous growths in the central nervous system, skin, heart, liver, and eyes. Diagnosis is by biopsy showing positive reactivity with monoclonal antibody HMB45 (1) , which recognizes the gp100 melanocytic protein, or by high-resolution computed tomography scan revealing characteristic pulmonary cysts plus the presence of TSC, angiomyolipoma (AML), lymphangioleiomyoma (LLM, lymphatic masses due to dilation of lymph vessels) (2), or high serum concentrations of vascular endothelial growth factor (VEGF)-D (3) .
The LAM cell is most commonly defined as an abnormal smooth muscle-like cell with inactivating mutations in TSC1 (chromosome 9q34; encoding hamartin) or, predominantly, TSC2 (16p13; tuberin). In addition, several molecular markers are beginning to emerge as characteristic LAM cell antigens (Table 1) . Hamartin and tuberin negatively regulate the mechanistic target of rapamycin (mTOR), such that deficiency/dysfunction of hamartin or tuberin leads to constitutive activation of mTOR and uncontrolled cell growth and proliferation, usually quantified by an increase in phospho-S6 kinase (4, 5) . mTOR inhibitors, such as rapamycin (sirolimus), are the only proven therapy for LAM, but although rapamycin slows LAM cell proliferation, it does not cause cell death (6) (7) (8) . The origin of the LAM cell is unknown. Here, we examine what is known about the LAM lung cell and contrast/compare that to knowledge from models of human cells used to study LAM. This review focuses on the human LAM cell and excludes the valuable animal models (reviewed in Reference 9).
LAM Cell Genetics
LAM cells are usually characterized by TSC2-inactivating mutations or loss of heterozygosity (LOH) of specific microsatellite markers on chromosome 16 (4, 10, 11) . Due to the prevalence of AMLs in patients with sporadic LAM (12), TSC2 LOH (10) and somatic TSC2 mutations (4) were first identified in DNA isolated from renal AMLs. Identical mutations were found in cells microdissected from the LAM lung as in the tissue from the corresponding AML (4), and TSC2 LOH was also identified, supporting Knudson's "two-hit" tumor suppressor gene model (13) (Figure 2 ). The AML and pulmonary LAM cells were concordant for LOH at each microsatellite marker, thus suggesting a common genetic origin for AML and pulmonary LAM (4) .
Because sporadic LAM results from somatic, and not germline, mutations (Figure 2) , it is often difficult to isolate a sufficiently pure population of "tumor" cells to successfully sequence or perform LOH analysis or biochemical assays without the data from the wild-type cells overwhelming the analysis. Badri and colleagues (14) used next-generation sequencing to look for TSC2 mutations in DNA isolated from microdissected LAM lung nodules from 10 patients with sporadic LAM. TSC2 mutations were found in eight samples, with variant frequencies ranging from 4% to 60%, despite the enrichment of sample by microdissection. Four of the eight had a detectable second-hit inactivation of TSC2 (three with LOH, one with a second mutation), whereas four had such low mutation frequencies for the first TSC2 mutation that it was difficult to experimentally detect LOH. Interestingly, two of the samples had neither a TSC2 nor TSC1 mutation, and had no evidence of mTOR activation, as determined by the presence of phospho-S6 kinase. These studies underline the importance of cell enrichment for genetic analysis and suggest that alternative genetic changes may be present in LAM.
LAM Cells in Tissues
LAM lung nodules are composed of more proliferative spindle-shaped cells and less proliferative, differentiated epithelioid cells, both of which express a-smooth muscle actin (1, 5, 15) . The epithelioid cells are more likely to react with HMB45 (15-95% of cells are reactive in lung biopsy or transplant tissue) (16) . LAM nodules also contain type II pneumocytes, lymphatic endothelial cells, and mast cells (17) (18) (19) . Wild-type fibroblast-like cells have been identified in LAM lung nodules that may provide the proper environment for LAM cell growth (20) . Reactivity to antibodies to highmobility group A2 was detected in all lung tissue samples from 21 patients with LAM, and it is suggested that misexpression of this gene activates a tumorigenic pathway, leading to a benign mesenchymal tumor (21) .
Lung biopsy and transplant tissue from patients with sporadic LAM revealed strong positive reactivity with an anti-podoplanin antibody in LAM cells and lymphatic endothelial cells (16) , which line enlarged lymphatic capillaries infiltrating the LAM lung nodules (18) . Antibodies to lymphatic markers (e.g., vascular endothelial growth factor receptor [VEGFR]-3) show more reactivity in tissue from late-stage LAM (lung explant) than early-stage LAM (lung biopsy) (16) . By immunohistopathology, LAM lung nodules are reactive to antibodies against diverse molecules, including hormone and chemokine receptors (summarized in Table 1 ). The different protein markers on LAM cells from several sources suggest a potential process of cell differentiation within specific microenvironments, and may also suggest that the gene expression of these markers is modified by the cell's microenvironment (e.g., soluble factors, cell-cell interaction).
AMLs are composed of smooth muscle, fat, and vascular components. Both isolated smooth muscle cells and fat cells exhibit TSC2LOH. Five different vessel types were identified in AMLs from four patients with sporadic LAM: cellular, collagenous, hemangiopericytic, glomeruloid, and aneurysmatic (22 lymph nodes or lymphatic vessels, leading to lymphangioleiomyoma, adenopathy, and/or chylous effusions. LAM cell clusters, nests of HMB45-positive LAM cells enveloped by lymphatic endothelial cells that express VEGFR-3 and podoplanin, have been identified in chylous fluid, the uterus, and within the lumen of lymphatic vessels that infiltrate the LAM nodule (23, 24) . VEGF-D and VEGFR-3 were also detected in LAM lung nodules (18) . Because serum VEGF-D levels correlate with the degree of lymphatic involvement and disease severity (25, 26) , it has been proposed that VEGF-D, acting through VEGFR-3, may facilitate the growth of lymphatic vessels in the LAM nodule and be involved in metastasis.
Human LAM Cell Models Pulmonary
Cultures of cells derived from LAM lung, after biopsy or transplant, grow as a mixture of TSC2 wild-type and TSC2-null cells, with increased activation of mTOR (5, 27 ). These cells also took on a lymphatic endothelial phenotype with expression of markers such as VEGFR-3 and podoplanin, suggesting a lymphatic origin for the LAM cell (35) .
Lesma and colleagues isolated cells from AMLs from a female (36) and male patient with TSC (37). Although both cell lines had germline mutations in TSC2, one line had TSC2LOH, whereas the other had promoter methylation, and thereby epigenetic silencing, of TSC2. The cell lines expressed CD44v6, and both required epidermal growth factor for growth.
Skin
Because of the challenges obtaining a homogeneous clonal population of TSC2-null pulmonary cells, we have used other (29) VEGF-C (23), VEGF-D (25) CCL2 (42) tumors with loss of TSC1 or TSC2, especially skin tumors, to gain insights that have shown relevance to LAM. Patients with TSC are predisposed to developing tumors in multiple organs (Figure 1 ) due to germline mutation in TSC1 or TSC2 (38) (Figure 2 ). We found that TSC skin tumors (39) contain fibroblast-like cells with two inactivating mutations in TSC1 or TSC2, and that primary cells from some TSC skin tumors are greatly enriched for two-hit cells (40) . Studies using these TSC skin tumor cells have advanced LAM research. The observation of increased CD9 expression in TSC skin tumor cells led to successful use of this marker in the enrichment of LAM cells from BAL fluid (BALF) and urine (41) . TSC skin tumor cells overexpressed CCL2 (42) , and this chemokine was also implicated in LAM pathogenesis (43) . TSC skin tumor cells were used to show that erythropoietin, a factor that may increase disease progression in LAM, stimulates the proliferation of TSC2 2/2 cells more than TSC2 1/2 cells (44). Cells grown from TSC skin tumors and normal-appearing skin were reprogrammed into TSC2 1/2 iPSC lines that recapitulate features of LAM (28) .
Skin tumor cells have also been used to create a xenograft model for TSC. The incorporation of TSC2-null cells into skin xenografts in mice causes histological changes that mimic those observed in native tumors (e.g., increased blood vessels, proliferation of the overlying epidermis, recruitment of mononuclear phagocytes) (45) . Treatment with sirolimus reverses these abnormalities in xenografts (45) and improves patient skin lesions when given orally (46) or topically (47) . It is notable that these improvements were observed despite the continued presence of TSC2-null cells in treated xenografts (45) and patients (46) .
Circulating Cells
LAM cells, as defined by TSC2LOH, have been isolated from blood, urine, expectorated chyle, pleural and abdominal chylous fluids, and BALF (41, (48) (49) (50) . As with tissue, circulating LAM cells need to be enriched to be studied genetically. Density gradient centrifugation of blood is used to enrich tumor cells, followed by FACS with CD45 and CD235a (41, 48) . Circulating LAM cells are found independent of disease stage (41, 48) . Cells with TSC2LOH were found in urine, mostly in patients with AMLs, and in chylous fluid (41), after FACS with antibodies to CD44v6 and CD9, prometastatic molecules that may enable cell mobilization and anchorage to sites of metastasis (41) .
LAM cells isolated from different body fluids are phenotypically different: LAM cells from urine and BALF cannot be isolated using anti-CD45 and antiCD235a antibodies, and those from blood cannot be isolated with anti-CD44v6 and anti-CD44 or anti-CD44v6 and anti-CD9 antibodies (41) . In most patients with sporadic LAM, LAM cells isolated from different body fluids of the same patient showed identical TSC2LOH patterns for specific microsatellites, consistent with a common genetic origin. However, almost 26% of patients had different patterns of TSC2LOH in blood subpopulations (51) , suggesting that a patient may have different clones of LAM cells. Different patterns of TSC2LOH were also detected in cells from blood versus urine (51) . Cells with TSC2LOH were isolated from blood of patients with LAM after bilateral lung transplantation, suggesting that circulating LAM cells may originate from somewhere other than the lung (51) . Treatment with rapamycin significantly decreased, in a timedependent manner, the ability to detect cells with TSC2LOH in blood and urine (49) .
The specificity of TSC2LOH in circulating cells as a marker for LAM is not definitive, although it may be a useful marker when coupled with clinical data. In a recent study analyzing samples from patients with different lung diseases (52), cells from blood and urine were isolated and analyzed for TSC2LOH. TSC2LOH was found in a patient with sarcoidosis in the CD9 2 CD44v6 2 cell population from urine and in a case of pulmonary Langerhans cell histiocytosis in unsorted blood cells. Interestingly, one patient with pulmonary Langerhans cell histiocytosis showed TSC2LOH in cells expressing CD1a, a marker of Langerhans cells. Cells with TSCLOH have been found in patients with cancers, including lung cancer, supporting the hypothesis that TSCLOH could be a common event in different cancerous processes.
Conclusions
The phenotype of a LAM cell differs according to its source. The biomarkers that are constant across different types of human LAM cells have not been determined rigorously (Table 1) . LAM cells may retain the potential to differentiate (e.g., the different kinds of LAM cells in an AML) or may retain stem cell characteristics. Mutations in TSC2 also define a LAM cell, although other genetic/biochemical changes cannot be ruled out. The presence of TSC2LOH may be diagnostic only with the presence of other clinical factors or cell surface markers. The origin of the LAM cell remains elusive. n Author disclosures are available with the text of this article at www.atsjournals.org. . LAM may be sporadic or occur in association with TSC. In sporadic LAM, germline TSC1/TSC2 are intact, but mutation of one allele of TSC1 or TSC2, followed by deletion of a region of the other allele near TSC1 or TSC2 (causing loss of heterozygosity) in somatic cells results in TSC2-null LAM cells. In TSC/LAM, germline TSC1 or TSC2 is mutated, resulting in somatic cells with mutations and eventual deletion of a region of the chromosome in the vicinity of TSC1 or TSC2. The asterisk indicates a mutation, and the dash indicates a deletion.
